Dose-finding Study of Hexaminolevulinate (HAL) Photodynamic Therapy (PDT) to Treat Cervical Neoplasia


An effective and safe medical therapy would be most welcome to reduce the need for surgical interventions and related adverse events and psychological impact on patients with cervical cancer precursors. In this clinical trial, the investigators propose to evaluate the efficacy and safety of photodynamic therapy (PDT) using hexaminolevulinate (HAL) for mild to moderate-grade CIN (grade 1-2).

Full Title of Study: “A Randomized Phase II Dose-finding Study of Hexaminolevulinate (HAL) Photodynamic Therapy (PDT) in Patients With Low/Moderate-grade Cervical Intraepithelial Neoplasia (CIN1 or 2)”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: September 2012


  • Drug: HAL 5% with illumination
    • Treatment with a singe dose of 2g, HAL 5% ointment followed by photoactivation
  • Drug: HAL 1% with illumination
    • Treatment with a singe dose of 2g, HAL 1% ointment followed by photoactivation
  • Drug: HAL 0.2% with illumination
    • Treatment with a singe dose of 2g, HAL 0.2% ointment followed by photoactivation
  • Drug: Placebo ointment without illumination
    • Treatment with a singe dose of 2g placebo ointment, no photoactivation

Arms, Groups and Cohorts

  • Experimental: HAL 5% with illumination
    • HAL PDT 5%
  • Experimental: HAL 1% with illumination
    • HAL PDT 1%
  • Experimental: HAL 0.2% with illumination
    • HAL PDT 0.2%
  • Placebo Comparator: Placebo ointment without illumination
    • Placebo without illumination

Clinical Trial Outcome Measures

Primary Measures

  • Comparison of Lesion Response Rates of Three Different Doses of HAL PDT and Placebo at 3 Months After Treatment.
    • Time Frame: 3 months after last treatment
    • Lesion response was defined by three variables: Histology, cytology and HPV. Patient response at three months required histology regression to CIN1 or normal, cytology of LSIL or less severe, and HPV negative.

Secondary Measures

  • Comparison of HPV Response of Three Different Doses of HAL PDT and Placebo at 3 Months After Treatment.
    • Time Frame: 3 months after treatment
    • HPV response was defined as clearance of baseline HPV infection, asssessed by genotype

Participating in This Clinical Trial

Inclusion Criteria

  • Patients with ectocervical CIN1 or CIN2 as verified by local pathology (biopsy) obtained within the last month – Satisfactory colposcopy examination including: – visibility of entire transformation zone including the squamocolumnar junction and – visibility of entire lesion margin – Negative endocervical os by colposcopy – Colposcopical visible lesion at visit 2, before treatment – Patients with an average sized uterine cervix (approximately 27mm diameter) suitable for application of the Klemcap – Age 18 or above – Written informed consent signed Exclusion Criteria:

  • Previous treatment of CIN or invasive disease – Lesion(s) extending to the vaginal vault – Atypical glandular cells (AGC) or adenocarcinoma in situ (AIS) on cytology, malignant cells on cytology or histology or other suspicion of either micro-invasive or invasive disease – Suspicion of endocervical disease on colposcopy – Current severe pelvic inflammatory disease, severe cervicitis, or other severe gynaecological infection as per colposcopy and clinical examination – Undiagnosed vaginal bleeding – History of toxic shock syndrome – Known or suspected porphyria – Known allergy to hexaminolevulinate or similar compounds (e.g. methyl aminolevulinate or aminolevulinic acid) – Pregnancy, or intention to become pregnant during the study period – Nursing – Childbirth or miscarriage within six weeks of enrolment – Use of heart pacemaker – Participation in other clinical studies either concurrently or within the last 30 days – Risk of poor protocol compliance. Patient participation should be considered with respect to living far away from the hospital, plans for moving to another city/state, frequent travelling, planning to become pregnant, drug abuse/alcoholic, difficult working hours, family obligations, other illness (e.g. psychiatric), etc. – Unwillingness to use adequate birth control (not abstinence) from screening until last PDT – Patient is the investigator or any sub-investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol

Gender Eligibility: Female

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Photocure
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Peter Hillemanns, MD, PhD, Principal Investigator, University Hospital Hannover

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.